Literature DB >> 604109

Strain-specificity of antibody to haemagglutinin following inactivated A/port chalmers/1/73 vaccine in man: evidence for a paradoxical strain-specific antibody response.

G C Schild, J W Smith, L Cretescu, R W Newman, J M Wood.   

Abstract

An analysis was carried out of the anti-haemagglutinin antibody responses in adult human recipients of inactivated whole virus A/Port Chalmers/1/73 (H3N2) vaccine using single radial diffusion combined with antibody adsorption techniques to determine antibody specificity. Antibody was characterised as cross-reactive (i.e. directed against antigenic determinants of haemagglutinin which are common for viruses within the H3 subtype) or strain-specific. Strain-specific antibodies for the vaccine strain and also for A/Hong Kong/68(H3N2) virus were assayed. A high proportion of vaccinees developed antibody of the cross-reactive specificity. The titre and frequency of such antibody increased with vaccine dose (100 iu to 1600 iu per dose). Many individuals developed strain-specific in addition to cross-reactive antibodies. A notable finding was that in 70% of vaccinees who developed strain-specific antibody, this was a paradoxical response directed against the strain specific determinant of A/Hong Kong/68 virus (the first number of the H3 subtype). Only 30% developed strain-specific antibody to the haemagglutinin of the vaccine strain. The percentage of vaccinees developing strain-specific antibodies to the vaccine strain was not significantly increased by increasing the dose of vaccine to 1600 iu. A second dose of A/Port Chalmers/73 vaccine administered approximately one year after the first dose only slightly increased the percentage with A/Port Chalmers strain-specific antibody.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 604109

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  11 in total

1.  Long-term study of influenza in families.

Authors: 
Journal:  J R Coll Gen Pract       Date:  1981-06

2.  Influenza 1980-1.

Authors: 
Journal:  Br Med J       Date:  1980-08-23

3.  Sequential infection or immunization of ferrets with a series of influenza A (H3N2) strains (report to the Medical Research Council's Sub-Committee on influenza Vaccines (CDVIP/IV)).

Authors:  C W Potter; R Jennings; M J Ali; J M Wood; U Dunleavy; D A Tyrrell
Journal:  Epidemiol Infect       Date:  1987-10       Impact factor: 2.451

4.  The specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccines and by natural infection.

Authors:  J S Oxford; G C Schild; C W Potter; R Jennings
Journal:  J Hyg (Lond)       Date:  1979-02

5.  Detection of antibodies to strain-specific and cross-reactive antigenic determinants on the haemagglutinin of influenza viruses A/Texas/1/77 and A/Bangkok/1/79 in human sera. Brief report.

Authors:  G Mancini; I Donatelli; G Arangio Ruiz; C Rozera
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

6.  The influenza virus: Antigenic composition and immune response.

Authors:  G C Schild
Journal:  Postgrad Med J       Date:  1979-02       Impact factor: 2.401

7.  Antibody responses after repeated influenza A virus immunizations among schoolchildren in Japan.

Authors:  N Yamane; M Hiratsuka; J Arikawa; T Odagiri; N Ishida
Journal:  J Hyg (Lond)       Date:  1981-12

8.  Studies with inactivated equine influenza vaccine. 1. Serological responses of ponies to graded doses of vaccine.

Authors:  J M Wood; J Mumford; C Folkers; A M Scott; G C Schild
Journal:  J Hyg (Lond)       Date:  1983-06

9.  Quantitation and analysis of the specificity of post-immunization antibodies to influenza B viruses using single radial haemolysis.

Authors:  J S Oxford; R Yetts; G C Schild
Journal:  J Hyg (Lond)       Date:  1982-04

10.  Studies with inactivated equine influenza vaccine. 2. Protection against experimental infection with influenza virus A/equine/Newmarket/79 (H3N8).

Authors:  J Mumford; J M Wood; A M Scott; C Folkers; G C Schild
Journal:  J Hyg (Lond)       Date:  1983-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.